Valuation
- Market cap
- 3,521,125,000
- Revenue TTM
- $517,150,000
- Net income TTM
- $66,350,000
- PE ratio
- 28.37
- Forward PE
- 32.67
- Profit margin
- 12.83%
- Debt to equity
- 0.00
Trading
- Volume
- 1,136,400
- Avg volume
- 1,343,416
- Day's range
- $43.47 – $45.17
- Shares out
- 80,391,000
- Stochastic %K
- 72%
- Beta
- 1.95
- Analysts
- Strong Sell
- Price target
- $57.62
Company profile
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diag...
Show more
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
- Industry
- Diagnostics & Research
- Sector
- Healthcare
- Phone
- 650 243 6300
- Website
- https://www.veracyte.com
- Address
- 6000 Shoreline Court, Suite 300, South San Francisco, United States
Latest news
No headlines yet.
